Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$41.80 USD

41.80
478,250

+0.02 (0.05%)

Updated Jul 23, 2024 04:00 PM ET

After-Market: $41.84 +0.04 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cardiovascular Systems Expands Portfolio Amid Stiff Rivalry

by Zacks Equity Research

Cardiovascular Systems (CSII) continues to expand its portfolio to widen the company's reach. However, Cardiovascular Systems operating in a highly competitive environment is a concern.

Neogen's Canadian Lab Buyout to Boost Genomics Business

by Zacks Equity Research

Neogen (NEOG) continues to adopt initiatives to boost the genomics business.

LabCorp Rides on Covance Business Amid Reimbursement Woes

by Zacks Equity Research

Within Covance Drug Development business, LabCorp (LH) aims at reaping huge profits via expanded solutions and better operational skills.

Omnicell (OMCL) Rides on Innovation Despite Cost Concerns

by Zacks Equity Research

Omnicell (OMCL) steadily sees a solid uptake of Omnicell XT. It also strikes various deals for the XR2 and IVX Workflow products.

LabCorp, GENFIT Tie-Up to Develop Test for NASH, Widen Suite

by Zacks Equity Research

LabCorp (LH) continues to strengthen foothold in the diagnostics space through organic and inorganic means.

Here's Why You Should Add CVS Health to Your Portfolio Now

by Zacks Equity Research

CVS Health (CVS) is optimistic about synergies from Aetna deal which will help create a robust platform to serve individuals better.

Solid Global Business Aids NuVasive Amid Pricing Pressure

by Zacks Equity Research

Per NuVasive (NUVA), the international region holds significant growth opportunity. However, pricing pressure is a major headwind.

Cardiovascular Systems Gets Approvals in Japan, Widens Suite

by Zacks Equity Research

Cardiovascular Systems (CSII) continues to expand product portfolio to enhance market reach and versatility.

Sreyoshi Mukherjee headshot

Has the Trade Debacle Ended for US MedTech Space? 3 Picks

by Sreyoshi Mukherjee

As the trade war fears slowly dissipate, let's take a look at three profitable U.S. MedTech picks.

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

by Zacks Equity Research

Amedisys (AMED) is developing and acquiring new business lines that will complement its existing home care and hospice business.

Walgreens Counts on International Progress, Strategic Deals

by Zacks Equity Research

We are upbeat about Walgreens' (WBA) recent pact with Alphabet???s life sciences and healthcare segment, Verily, to coordinate on multiple projects with respect to chronic ailments.

Cardiovascular Systems Treats First Patient With Teleport

by Zacks Equity Research

Cardiovascular Systems (CSII) expands product portfolio to enhance market reach and versatility.

Here's Why You Should Invest in Hill-Rom (HRC) Stock Now

by Zacks Equity Research

Hill-Rom's (HRC) M&A pipeline continues to be strong.

Boston Scientific (BSX) to Buy Residual Shares of Millipede

by Zacks Equity Research

Boston Scientific's (BSX) buyout of the leftover stake in Millipede will integrate the latter's IRIS Transcatheter Annuloplasty Ring System in the Structural Heart portfolio of the former.

Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth

by Zacks Equity Research

Zimmer Biomet (ZBH) is performing well on the back of its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application.

Medtronic's Growth Across All Lines Aid, Rising Costs Ail

by Zacks Equity Research

Of late, Medtronic (MDT) succeeds in delivering solid top-line growth at CER, backed by balanced growth across major business operation.

Myriad Genetics Posts Positive Adjusted Vectra Test Data

by Zacks Equity Research

The key finding of Myriad Genetics' (MYGN) study proves that the adjusted Vectra score beats all traditional measures of disease activity to predict radiographic progression in RA patients.

SYK vs. SRDX: Which MedTech Stock Should Investors Pick?

by Zacks Equity Research

Surmodics (SRDX) scores higher than Stryker (SYK) in terms of current-year revenue projections and fundamentals.

Here's Why You Should Buy Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

As a result of continued efforts to streamline operations, Integer Holdings (ITGR) has been registering strong profits over the last couple of quarters.

Here's Why You Should Invest in Genomic Health (GHDX) Now

by Zacks Equity Research

Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now expanding considerably in the international arena.

Hill-Rom Grows on Acquisitions, Asia Pacific Sales Drop

by Zacks Equity Research

Hill-Rom (HRC) is actively pursuing buyouts to accelerate growth across five key clinical areas.

Here's Why You Should Invest in Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) continues to gain from its Mako robotics platform, which has been the key driver of the company's core Orthopaedic segment.

Walgreens (WBA) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Walgreens' (WBA) retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market.

Walgreens-Alphabet Join Forces to Control Healthcare Costs

by Zacks Equity Research

Walgreens (WBA) and Alphabet's arm Verily to start a medication adherence pilot project that will deploy equipment and other methods to improve adherence.

Here's Why You Should Invest in STERIS (STE) Stock Right Now

by Zacks Equity Research

With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS (STE) has become the global leader in infection prevention and sterilization.